Research Program: Transplant Biology & Therapy
Professor, Department of Medicine, Division of Hematology, Oncology and Transplantation

burns019@umn.edu
612-624-8144 — office
Preferred contact method: e-mail

Dr. Burns' clinical profile
(University of Minnesota Physicians Web site)

Dr. Burns received her M.D. in 1981 from the University of Missouri-Columbia. She completed residency training in internal medicine as well as subspecialty hematology and medical oncology training at the University of Iowa. Dr. Burns has been a member of the faculty at the University of Minnesota since 1992, and has been the fellowship director of the Hematology, Oncology and Fellowship (HOT) Division since 1998.

Research Interests

Hematologic malignancies, hematopoietic stem cell transplantation, late effects of transplantation.

Dr. Burns research focuses on experimental immunotherapies for malignant hematologic disorders including lymphoma and leukemia and complications of hematopoietic stem cell transplantation including infections, second cancers and late effects. She is currently conducting a phase I clinical trial investigating the use of an anti-CD45 radiolabeled antibody developed by collaborators in the Cancer Center for patients with relapsed/refractory non-Hodgkin's lymphoma and leukemia. Clinical studies of late effects of transplantation include an interventional study to prevent osteoporosis and treatment of transfusional iron overload in transplant recipients.

Selected Publications

Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortar A, Kuroki DW, Wagner JE, Vitetta ES, Kersey JH. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 2004; 19:11-23.

Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA matched sibling donor hematopoietic stem cell transplant after reduced-intensity preparative regimen for advanced Hodgkin's lymphoma. Blood. 2006 May 1;107(9):3804-7.

Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socie G. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: join recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12:138-51.

Majhail NS, Defor TE, Weisdorf DJ, Burns LJ. Long term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma: Single institution experience over a 20-year period. Biol Blood Marrow Transplant. 12:1065-72, 2006.

Klein MA, Kadidlo D, McCullough J, McKenna DH, Burns LJ. Microbial contamination of hematopoietic stem cell products: Incidence and clinical sequelae. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. 12:1142-9, 2006.

Lerner R, Thomas W, DeFor T, Weisdorf DJ, Burns LJ. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 13:486-92, 2007.

Vallera DA, Sicheneder AR, Taras EP, Brechbiel MW, Vallera JA, Panoskaltsis-Mortari A, Burns LJ. Radiotherapy of CD45 expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody. Cancer Biother and Radiopharm. 22:488-500, 2007.

Bunte MC, Patnaik MM, Pritzker MR, Burns LJ. Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplant. 1008, Jan 28, 2008 [Epub]